Morgan Stanley trimmed its position in shares of Sienna Biopharmaceuticals Inc (NASDAQ:SNNA) by 15.4% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 734,478 shares of the company’s stock after selling 134,049 shares during the quarter. Morgan Stanley owned approximately 2.38% of Sienna Biopharmaceuticals worth $639,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other institutional investors have also recently made changes to their positions in the company. Paloma Partners Management Co acquired a new stake in shares of Sienna Biopharmaceuticals during the 2nd quarter valued at about $60,000. Vanguard Group Inc. lifted its holdings in shares of Sienna Biopharmaceuticals by 95.3% during the 2nd quarter. Vanguard Group Inc. now owns 1,859,306 shares of the company’s stock valued at $1,617,000 after buying an additional 907,318 shares during the last quarter. A.R.T. Advisors LLC lifted its holdings in shares of Sienna Biopharmaceuticals by 84.5% during the 2nd quarter. A.R.T. Advisors LLC now owns 32,653 shares of the company’s stock valued at $28,000 after buying an additional 14,954 shares during the last quarter. Canada Pension Plan Investment Board acquired a new stake in shares of Sienna Biopharmaceuticals during the 2nd quarter valued at about $26,000. Finally, Renaissance Technologies LLC lifted its holdings in shares of Sienna Biopharmaceuticals by 92.1% during the 2nd quarter. Renaissance Technologies LLC now owns 586,294 shares of the company’s stock valued at $510,000 after buying an additional 281,094 shares during the last quarter. Institutional investors and hedge funds own 45.64% of the company’s stock.
Shares of SNNA stock opened at $0.15 on Friday. The stock’s 50 day simple moving average is $0.19 and its 200 day simple moving average is $0.84. The company has a debt-to-equity ratio of 1.11, a quick ratio of 2.43 and a current ratio of 2.43. The company has a market capitalization of $5.38 million, a price-to-earnings ratio of -0.04 and a beta of 2.66. Sienna Biopharmaceuticals Inc has a twelve month low of $0.10 and a twelve month high of $11.39.
Sienna Biopharmaceuticals (NASDAQ:SNNA) last announced its quarterly earnings results on Thursday, August 8th. The company reported ($0.27) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.43) by $0.16. On average, analysts forecast that Sienna Biopharmaceuticals Inc will post -3.1 EPS for the current fiscal year.
A number of brokerages recently weighed in on SNNA. ValuEngine downgraded Sienna Biopharmaceuticals from a “buy” rating to a “hold” rating in a research note on Friday, October 25th. BMO Capital Markets cut their price objective on Sienna Biopharmaceuticals to $3.00 and set an “outperform” rating on the stock in a research note on Thursday, September 5th. Three investment analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. The company has an average rating of “Hold” and an average target price of $17.00.
Sienna Biopharmaceuticals Company Profile
Sienna Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of drugs in various therapeutic areas. It develops therapies in immunology and inflammation that target select pathways in tissues, such as skin. The company's lead product candidates include SNA-120, a first-in-class inhibitor of tropomyosin receptor kinase A, which is in a Phase IIb clinical trial for the treatment of psoriasis and associated pruritus; and SNA-125, a topical dual Janus kinase 3 inhibitor that is in Phase I/II clinical trials for the treatment of atopic dermatitis, psoriasis, and pruritus.
See Also: What is meant by a buy rating?
Want to see what other hedge funds are holding SNNA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sienna Biopharmaceuticals Inc (NASDAQ:SNNA).
Receive News & Ratings for Sienna Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sienna Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.